Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Aline Raquel Voltan,1 Guillermo Quindós,2 Kaila P Medina Alarcón,3 Ana Marisa Fusco-Almeida,3 Maria José Soares Mendes-Giannini,3 Marlus Chorilli1 1Department of Drugs and Medicines, Faculty of Pharmaceutical Sciences, Univ. Estadual Paulista, Araraquara, Sao Paulo,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Voltan AR, Quindós G, Alarcón KPM, Fusco-Almeida AM, Mendes-Giannini MJS, Chorilli M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Fungal diseases antifungal agents amphotericin B azoles nanoparticles nanotechonology. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/38a15c3f38c44a339da89468d8d53858
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:38a15c3f38c44a339da89468d8d53858
record_format	dspace
spelling	oai:doaj.org-article:38a15c3f38c44a339da89468d8d538582021-12-02T00:04:48ZFungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?1178-2013https://doaj.org/article/38a15c3f38c44a339da89468d8d538582016-08-01T00:00:00Zhttps://www.dovepress.com/fungal-diseases-could-nanostructured-drug-delivery-systems-be-a-novel--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Aline Raquel Voltan,1 Guillermo Quindós,2 Kaila P Medina Alarcón,3 Ana Marisa Fusco-Almeida,3 Maria José Soares Mendes-Giannini,3 Marlus Chorilli1 1Department of Drugs and Medicines, Faculty of Pharmaceutical Sciences, Univ. Estadual Paulista, Araraquara, Sao Paulo, Brazil; 2Immunology, Microbiology, and Parasitology Department, Facultad de Medicina y Odontología, Universidad del País Vasco, Bilbao, Spain; 3Department of Clinical Analysis, Faculdade de Ciências Farmacêuticas, Univ. Estadual Paulista, Araraquara, Sao Paulo, Brazil Abstract: Invasive mycoses are a major problem for immunocompromised individuals and patients in intensive care units. Morbidity and mortality rates of these infections are high because of late diagnosis and delayed treatment. Moreover, the number of available antifungal agents is low, and there are problems with toxicity and resistance. Alternatives for treating invasive fungal infections are necessary. Nanostructured systems could be excellent carriers for antifungal drugs, reducing toxicity and targeting their action. The use of nanostructured systems for antifungal therapy began in the 1990s, with the appearance of lipid formulations of amphotericin B. This review encompasses different antifungal drug delivery systems, such as liposomes, carriers based on solid lipids and nanostructure lipids, polymeric nanoparticles, dendrimers, and others. All these delivery systems have advantages and disadvantages. Main advantages are the improvement in the antifungal properties, such as bioavailability, reduction in toxicity, and target tissue, which facilitates innovative therapeutic techniques. Conversely, a major disadvantage is the high cost of production. In the near future, the use of nanosystems for drug delivery strategies can be used for delivering peptides, including mucoadhesive systems for the treatment of oral and vaginal candidiasis. Keywords: fungal diseases, antifungal agents, amphotericin B, azoles, nanoparticles, nanotechnologyVoltan ARQuindós GAlarcón KPMFusco-Almeida AMMendes-Giannini MJSChorilli MDove Medical PressarticleFungal diseasesantifungal agentsamphotericin Bazolesnanoparticlesnanotechonology.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss default, Pp 3715-3730 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Fungal diseases antifungal agents amphotericin B azoles nanoparticles nanotechonology. Medicine (General) R5-920
spellingShingle	Fungal diseases antifungal agents amphotericin B azoles nanoparticles nanotechonology. Medicine (General) R5-920 Voltan AR Quindós G Alarcón KPM Fusco-Almeida AM Mendes-Giannini MJS Chorilli M Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
description	Aline Raquel Voltan,1 Guillermo Quindós,2 Kaila P Medina Alarcón,3 Ana Marisa Fusco-Almeida,3 Maria José Soares Mendes-Giannini,3 Marlus Chorilli1 1Department of Drugs and Medicines, Faculty of Pharmaceutical Sciences, Univ. Estadual Paulista, Araraquara, Sao Paulo, Brazil; 2Immunology, Microbiology, and Parasitology Department, Facultad de Medicina y Odontología, Universidad del País Vasco, Bilbao, Spain; 3Department of Clinical Analysis, Faculdade de Ciências Farmacêuticas, Univ. Estadual Paulista, Araraquara, Sao Paulo, Brazil Abstract: Invasive mycoses are a major problem for immunocompromised individuals and patients in intensive care units. Morbidity and mortality rates of these infections are high because of late diagnosis and delayed treatment. Moreover, the number of available antifungal agents is low, and there are problems with toxicity and resistance. Alternatives for treating invasive fungal infections are necessary. Nanostructured systems could be excellent carriers for antifungal drugs, reducing toxicity and targeting their action. The use of nanostructured systems for antifungal therapy began in the 1990s, with the appearance of lipid formulations of amphotericin B. This review encompasses different antifungal drug delivery systems, such as liposomes, carriers based on solid lipids and nanostructure lipids, polymeric nanoparticles, dendrimers, and others. All these delivery systems have advantages and disadvantages. Main advantages are the improvement in the antifungal properties, such as bioavailability, reduction in toxicity, and target tissue, which facilitates innovative therapeutic techniques. Conversely, a major disadvantage is the high cost of production. In the near future, the use of nanosystems for drug delivery strategies can be used for delivering peptides, including mucoadhesive systems for the treatment of oral and vaginal candidiasis. Keywords: fungal diseases, antifungal agents, amphotericin B, azoles, nanoparticles, nanotechnology
format	article
author	Voltan AR Quindós G Alarcón KPM Fusco-Almeida AM Mendes-Giannini MJS Chorilli M
author_facet	Voltan AR Quindós G Alarcón KPM Fusco-Almeida AM Mendes-Giannini MJS Chorilli M
author_sort	Voltan AR
title	Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
title_short	Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
title_full	Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
title_fullStr	Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
title_full_unstemmed	Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
title_sort	fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/38a15c3f38c44a339da89468d8d53858
work_keys_str_mv	AT voltanar fungaldiseasescouldnanostructureddrugdeliverysystemsbeanovelparadigmfortherapy AT quindosg fungaldiseasescouldnanostructureddrugdeliverysystemsbeanovelparadigmfortherapy AT alarconkpm fungaldiseasescouldnanostructureddrugdeliverysystemsbeanovelparadigmfortherapy AT fuscoalmeidaam fungaldiseasescouldnanostructureddrugdeliverysystemsbeanovelparadigmfortherapy AT mendesgianninimjs fungaldiseasescouldnanostructureddrugdeliverysystemsbeanovelparadigmfortherapy AT chorillim fungaldiseasescouldnanostructureddrugdeliverysystemsbeanovelparadigmfortherapy
_version_	1718403919794667520

Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Ejemplares similares